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A theoretically based cross-sectional survey on the behaviors and experiences of 
clinical pharmacists caring for patients with Chronic Kidney Disease. 
 
INTRODUCTION 
Chronic kidney disease (CKD) is defined as ‘progressive abnormalities of kidney 
structure and/or function over a period of time varying from weeks to months, 
with implications for health’.1 A recent systematic review and meta-analysis 
reported that the global prevalence of CKD, with a rate between 11% and 13%, 
is high compared to other diseases.2 The Kidney Disease Outcome Quality 
Initiative has classified the stages of CKD with linked action plans (Table 1).3 
Table 1: Stages of CKD: A clinical action plan 





1 Kidney damage with 
normal or ↑ GFR 
≥ 90 Diagnosis and treatment, treatment 
of comorbid conditions, slowing 
progression, cardiovascular disease 
(CVD) risk reduction 
2 Kidney damage with 
mild ↓ GFR 
60 - 89 Estimating progression 
3 Moderate ↓ GFR 30-59 Evaluating and treating complications 
4 Severe ↓ GFR 15-29 Preparation for kidney replacement 
therapy 
5 Kidney failure < 15 Replacement (if uremia present) 
CKD is defined as either kidney damage or GFR <60 ml/min/1.73m2 for ≥3 months. Kidney 
damage is defined as pathological abnormalities or markers of damage, including abnormalities in 
blood or urine tests or imaging studies.  
Adapted from Levey et al 3 
CKD is a complex comorbid condition with; high economic burden, reduced 
quality of life, frequent hospitalization, reduced life expectancy and high risk of 
mortality.1,2,4,5 Patients are prescribed an array of medications which can result 
in medication burden, potential for reduced adherence and increased adverse 
effects.6  In view of this, there is significant opportunity for pharmacists to 
contribute to the multidisciplinary care of CKD patients and so improve patient 
outcomes.7 A systematic review 9, published in 2012, included 37 peer-reviewed 
papers and aimed to assess the impact of pharmacists’ interventions on the 
management of patients with CKD. It reported that through the systematic 
provision of pharmaceutical care (i.e. person-focused care relating to medication 
with the aim of improving the outcomes of therapy and provided by a 
pharmacist and the pharmacy team 8) pharmacists have the potential to 
contribute significantly to the multidisciplinary team leading safe, effective and 
economic care for patients.9 A subsequent systematic review in 2019 aimed to 
critically appraise, synthesise and present the available evidence for the 
structures, processes and related outcomes of clinical pharmacy practice (i.e. 
pharmacists direct contribution to patient care and the development and 
promotion of the rational use of medication at any level of healthcare practice) 
as part of the multidisciplinary care of patients with CKD.10 The review included 
47 studies and reported that there is limited evidence on the structures and 
processes of care for patients with CKD. The review also reported some evidence 
for the outcomes of pharmacists’ interventions in patients with CKD but these 
studies were generally of low quality and insufficient volume. Controlled studies 
in the review showed that pharmacist interventions improved patients’ clinical 
outcomes such as hemoglobin concentration levels, creatinine clearance, 
parathyroid hormone and calcium levels. However, these studies lacked detail on 
reporting of the humanistic outcomes such as quality of life, patient satisfaction 
and functional status. The review also showed that there is also limited evidence 
demonstrating economic impact of pharmacists’ interventions.  
Of the studies identified, very few were of a ‘gold standard’ RCT design and the 
quality of other types of study with controls, that were included, was generally 
poor.9,10 RCTs lacked sufficient information on the randomisation and blinding 
processes so jeopardising the quality of these studies. Structures and processes 
were also very poorly reported with most papers lacking sufficient details of the 
clinical pharmacy practices. Without such information it is difficult to fully 
understand the context and characteristics of the models of practice so making 
transferability difficult. This lack of detail also greatly limits the potential to 
standardise data collection and pool data, particularly relating to outcomes. 
There were no studies that have specifically investigated prescribing as part of 
clinical pharmacy practice and there are no gold standard RCTs with full 
description of structure, processes and outcomes as they relate to prescribing 
practice.  
Generally, uncontrolled studies had a variety of quality deficiencies including; 
lack of comprehensive explanation of the pharmacists’ intervention, under-
reporting of adverse events and insufficient information to allow reproduction of 
the studies.  
A study by Yamamoto et al. showed a decline in hospital admissions from 71.4% 
to 38.1% (P = 0.03) after the pharmacists’ intervention.12 Another study 
included 204 patients reported that there was; a reduction in the average cost of 
medication, better therapeutic drug monitoring of immunosuppressive drugs 
within target levels and higher blood pressure control in the post-intervention 
group.13 A further recent example of the limited evidence in this area is a 
subgroup analysis of a randomized controlled trial that evaluated the effect of a 
community pharmacy-based intervention on estimation of cardiovascular (CV) 
risk in patients with CKD. This study showed that pharmacist-led care of patients 
with CKD reduced CV risk and improved control of CV risk factors.14 These 
studies highlight that the inclusion of pharmacists in a multidisciplinary team can 
improve patient outcomes. However, what is not clear from these studies, is the 
detail of the structures and processes required to achieve these outcomes. 
A major limitation of the evidence base to date is that few studies have used 
implementation theory for any part of the research process. It is increasingly 
recognised that underpinning research with suitable theoretical frameworks is 
essential. A range of frameworks have been developed by researchers and 
selecting the most suitable framework depends on the aim and type of research. 
An example is the Consolidated Framework for Implementation Research (CFIR) 
which consists of a menu of constructs that have been associated with effective 
implementation. It was developed from a review of 500 published sources across 
13 scientific disciplines and a range of other sources. It can be used to assess 
potential barriers and facilitators in preparation for implementing of an 
innovation. The use of theory throughout the research process can provide a 
more comprehensive and consistent approach to consider all factors associated 
with the research.11         
The UK Renal Pharmacy Group (UKRPG - www.renalpharmacy.org.uk) is a 
professional group that aims to support the development of pharmacists in the 
care of patients with CKD and to standardise structures and processes for 
practice. The group has developed a competency framework for pharmacists 
providing care to renal patients including those with CKD. This describes a broad 
range of clinical activities that can be provided and helps define general aspects 
of practice to support pharmacists in their career progression through advanced 
to the consultant-level renal clinical pharmacy practice.15 Despite the range of 
activities captured in the framework Al Raiisi et al 10 have shown that there is a 
paucity of quality research that clearly characterizes the structures and 
processes of this broad range of services related to care provision.  
Pharmacists can qualify as independent nonmedical prescribers in the UK and 
this permits them to prescribe, within their competence, the same range of 
medications as physicians.16,17 Prescribing models have also been implemented 
or trialled in several other countries such as; Canada, New Zealand, Australia 
and some states of the USA.17,18 While there is expanding recognition for the 
support of nonmedical prescribing at policy making levels 17,18 there still remains 
limited information relating to the detail of the models of nonmedical prescribing 
practice and this particularly true within the care of patients with CKD.  
There is therefore a need for more robust and rigorous research to describe and 
characterise fully the contribution of pharmacists. The aim of this study was to 
determine pharmacists’ behaviors and experiences and the barriers and 






This study was a cross-sectional survey using an online questionnaire. 
Setting  
The research was conducted in the UK using the membership of the UKRPG as 
the sampling frame. UKRPG is a not-for-profit organization established in the 
early 1980s and currently has in excess of 200 clinical and administrative 
members. The group includes pharmacists from across the UK and a few 
international members either practicing renal pharmacy or have interest in renal 
medicine. 
Participants 
Inclusion and exclusion criteria 
All pharmacists who are members of the UKRPG were invited to participate. 
Exclusion was for pharmacists not practicing clinically in the UK.  
 
Questionnaire development 
The development of the questionnaire tool followed an iterative process based 
on a comprehensive literature search including relevant electronic databases 
(PubMed, International Pharmaceutical Abstracts (IPA), Cumulative Index to 
Nursing and Allied Health Literature (CINAHL), and Scopus). This was in addition 
to the summary of research related to the topic identified from a recent 
systematic review conducted by the research team.10 This enabled the 
identification of key concepts and themes to be included in the draft 
questionnaire. Face and content validity testing were carried out by six expert 
researchers from an academic institution and pharmacist practitioners from 
secondary care. ‘Think aloud’ testing was carried out with three clinical 
pharmacists not involved in any other process of the questionnaire development. 
The final version of the questionnaire was developed in ‘Online Surveys’, JISC, 
UK (formerly Bristol Online Survey Tool®, https://www.jisc.ac.uk/online-
surveys), and piloted with a random sample of 14 (around 10% of the target 
population) members of the UKRPG. Piloting resulted in only minor formatting 
changes, so pilot data were included in the final dataset.  
At the outset of the questionnaire, an initial screening question identified those 
UKRPG members not practicing clinical pharmacy in the UK. Remaining items 
were grouped into sections of: demographics, clinical practice (characteristics 
and types of clinical pharmacy services provided for outpatients and inpatients) 
and prescribing practice (development and implementation of prescribing 
practice, model of prescribing, areas and frequency of prescribing). 
Questionnaire items were of various types including, where appropriate, closed 
type questions and some open questions to allow respondents to provide 
explanatory comments. Attitudinal type items on the development of clinical and 
prescribing practice used a 5-point Likert scale format. In the demographics 
section of the questionnaire, participants were asked to respond to a question 
relating to descriptors from Rogers Diffusion of Innovation theory these included 
whether they felt they were; ‘laggards’, ‘late majority’, ‘early majority’, ‘early 
adopters’ or ‘innovators’.19  
Items on development and implementation of clinical and prescribing practice 
were derived from the Consolidated Framework for Implementation Research 
(CFIR), which is based on the principles of implementation theory.11 CFIR 
includes five major domains (intervention characteristics: aspects on the 
intervention that may impact the implementation success, outer setting: 
external influences on intervention implementation, inner setting: characteristics 
of the implementing organization, characteristics of individuals: individuals 
attributes and belief towards the intervention and process: stages of 
implementation) with 39 underlying constructs and sub-constructs that can 
potentially influence efforts to change practice.11,20 The most relevant constructs 
were used to guide the development of the survey questions to ensure 
comprehensive coverage of the most important elements of the clinical and 
prescribing practice of pharmacists in the care of patients with CKD. 
Data collection 
An invitation email, with a link to the questionnaire and the participant 
information leaflet, was sent to the UKRPG coordinator to distribute to members. 
Evidence-based approaches were used to enhance the response rate,21 namely 
an information leaflet to outline study objectives and potential benefits, entry 
into a prize draw, and two reminders at monthly intervals. In addition, the lead 
researcher promoted the work at the annual UKRPG conference and encouraged 
the pharmacists to participant in the survey.  
Data were collected over a period of six weeks from 17th of September 2018 till 
28th of October 2018. 
Data analysis 
Data were analysed using descriptive statistics using Statistical Package for the 
Social Sciences SPSS® Statistics Version 25; the population size and number of 
respondents limited the potential for inferential analysis. Free text comments 
were analysed independently by two researchers by using the Framework 
Approach to qualitative data content analysis.22 
Ethical considerations   
The Ethical Review Panel of the School of Pharmacy and Life Sciences at Robert 
Gordon University, UK approved this study (S130). As the study recruited 
members of a professional network, formal National Health Service approval was 
not required.  
RESULTS 
Seventy-one responses were received from the 142 participants invited to take 
part giving a response rate of 50%. Of the 71 responses, seven were not 
currently practicing clinical pharmacy giving 64 responses for analysis.  
Table 2 summarizes demographics of the study participants. Almost three 
quarter were female (78.1%, n = 50) with just over half being 31-40 years of 
age (51.6%, n = 33). All were mainly practicing in secondary care setting as 
their main job sector (100%, n = 64), with (45.3%, n = 29) participants had 
experience of working in community pharmacy and very few in general practice 
(3.1%, n = 2) A majority of the respondents were practicing in England (75%, n 
= 48). Over a third (35.9%, n = 23) of the pharmacists have been providing 
care for patients with CKD for 1 – 5 years with 20.3% (n = 13) for 11 – 15 years 
and fifty-three (82.8%, n = 53) of respondents were non-medical prescribers.  
More than half of respondents (57.8%, n = 37) indicated that they ‘think for 
some time before adopting new ways of working’ which corresponds with the 
‘early majority’ category in Rogers Diffusion of Innovation.19 
 
Table 2: Demographic characteristics (N=64) 
Title Categories  n (%) 
Gender  Male 14 (21.9) 
Female 50 (78.1) 
Age  Less than 30 years 14 (21.9) 
31 - 40 years 33 (51.6) 
41 - 50 years 10 (15.6) 
51 - 60 years 7 (10.9) 
61 year and above 0 (0) 
Main job sector of practice  Secondary care 64 (100) 
Primary care 0 (0) 
GP practice 0 (0) 
Community pharmacy 0 (0) 
Other 0 (0) 
Geographical area of practice  England 48 (75) 
Scotland 10 (15.6) 
Wales 4 (6.3) 
Northern Ireland 2 (3.1) 
Academic qualifications (Multiple 
selection allowed) 
BSc 16 (10.2) 
MPharm 46 (29.3) 
Postgraduate diploma 49 (31.2) 
Postgraduate certificate 11 (7) 
MSc 16 (10.2) 
PhD 3 (1.9) 
Other 16 (10.2) 
Years qualified as a pharmacist less than a year 0 (0) 
1-5 years 9 (14.1) 
6-10 years 13 (20.3) 
11-15 years 17 (26.5) 
16 - 20 years 10 (15.6) 
More than 20 years 14 (21.9) 
Missing 1 (1.6) 
Years worked in hospital 
pharmacy  
Never worked in this sector 0 (0) 
Less than 1 year 1 (1.6) 
1-5 years 11 (17.2) 
6-10 years 12 (18.8) 
11- 15years 20 (31.3) 
16-20 years 8 (12.5) 
more than 20 years 12 (18.8) 
Years providing clinical care for 
patients with CKD 
less than a year 8 (12.5%) 
1-5 years 23 (35.9%) 
6-10 years 10 (15.6%) 
11-15 years 13 (20.3%) 
16 - 20 years 5 (7.8%) 
More than 20 years 5 (7.8%) 
Characteristics of the innovation  I resist new ways of working, I am cautious 
in relation to new ways of working (laggards) 0 (0) 
I tend to change once most of my peers have 
done so (late majority) 4 (6.3) 
I think for some time before adopting new 
ways of working (early majority) 37 (57.8) 
I serve as a role model for others in relation 
to new ways of working (early adopter) 10 (15.6) 
I am innovative with new ways of working 
(innovators) 13 (20.3) 
Nonmedical prescriber  Yes 53 (82.8) 
No 11 (17.2) 
 
Full data from the survey is provided in the tables 3 to 5 with key findings from 
each highlighted below.  
 
Clinical pharmacy services for inpatients 
All the respondents were providing care in the inpatient setting (n = 64) in a 
variety of areas as shown in table 3. The majority of respondents (87.5%, n = 
56) provided general pharmaceutical care, with pharmaceutical care specifically 
for dialysis patients provided by 84.4% (n = 54). Individual patient medication 
related education was provided by 85.9% (n = 55), while 81.3% (n = 52) of the 
respondents had regular meetings with the multidisciplinary team.  
 
Pharmaceutical care for transplantation patients was provided by 71.9% (n = 
46) of the respondents with such services provided with a variety of frequencies 
but by more than half (54.3%, n=25) on a daily basis during the working week.  
Medicines reconciliation was the most frequently provided service with 89.1% (n 
= 57) of respondents indicating that this service was provided throughout the 
week (i.e. daily weekdays and daily weekdays and weekends) by 85.9% (n=49)  
 
Consulting inpatients with different CKD related conditions was performed by 
almost three-quarter of the participants, with 76.6% (n = 49) consulting 
patients with mineral bone disease, acute kidney injury by 76.6% (n = 49), 
other renal complications by 71.9% (n = 46) and consulting inpatients on 
hemodialysis or peritoneal dialysis by 70.3% (n = 45). These consultations were 
provided mostly on daily basis on weekdays or on an ‘ad hoc’ basis by most of 
the participants in the inpatient setting. 
 
Compared to the above there were ‘Areas of care’ where respondents indicated 
they were less involved. Around two thirds of respondents indicated that they 
attended medical ward rounds with the multidisciplinary team (67.2%, n = 43) 
with a third of these (37.2%, n=16) indicating doing this on a daily basis during 
the working week. Targeted disease specific medication review services were 
also less developed with almost two thirds undertaking anemia targeted review 
(65.6%, n = 42), vasculitis by 68.8% (n = 44) and hypertension by 65.6% (n = 
42).   
Table 3: Characteristics of clinical pharmacy services you provide for INPATIENTS with CKD (N=64) 
Area of care 
Provision 










x/week Once/week Ad hoc  Missing 
n (%) n (%) n (%) n (%) n (%) n (%)  n (%) 
General pharmaceutical care  56 (87.5) 33 (58.9) 13 (23.2) 7 (12.5) 1 (1.8) 2 (3.6) 0 (0) 
Pharmaceutical care for patients receiving dialysis  54 (84.4) 32 (59.3) 8 (14.8) 6 (11.1) 2 (3.7) 6 (11.1) 0 (0) 
Pharmaceutical care for patients at transplantation /follow-
up 46 (71.9) 25 (54.3) 8 (17.4) 6 (13) 3 (6.5) 4 (8.7) 0 (0) 
Full medication regimen polypharmacy review 50 (78.1) 27 (54) 6 (12) 8 (16) 2 (4) 6 (12) 1 (2) 
Targeted CKD renal medication review  50 (78.1) 23 (46) 6 (12) 10 (20) 2 (4) 9 (18) 0 (0) 
Targeted renal medication review: transplantation  47 (73.4) 18 (38.3) 7 (14.9) 6 (12.8) 2 (4.3) 13 (27.7) 1 (2.1) 
Targeted renal medication review: vasculitis  44 (68.8) 13 (29.5) 3 (6.8) 5 (11.4) 1 (2.3) 22 (50) 0 (0) 
Targeted renal medication review: anemia  42 (65.6) 15 (37.5) 6 (14.3) 9 (21.4) 1 (2.4) 11 (26.2) 0 (0) 
Targeted renal medication review: hypertension  42 (65.6) 20 (47.6) 5 (11.9) 4 (9.5) 2 (4.8) 11 (26.2) 0 (0) 
Consulting inpatients with mineral bone disease  49 (76.6) 19 (38.8) 6 (12.2) 11 (22.4) 2 (4.1) 10 (20.1) 1 (2) 
Consulting inpatients with acute kidney injury  49 (76.6) 23 (46.9) 7 (14.3) 6 (12.2) 3 (6.1) 10 (20.4) 0 (0) 
Consulting inpatients with renal complication  46 (71.9) 24 (52.2) 7 (15.2) 9 (19.6) 0 (0) 6 (13) 0 (0) 
Consulting inpatients on hemodialysis or peritoneal dialysis  45 (70.3) 24 (53.3) 5 (11.1) 7 (15.6) 3 (6.7) 6 (13.3) 0 (0) 
Medicines reconciliation  57 (89.1) 34 (59.6) 15 (26.3) 3 (5.3) 2 (3.5) 2 (3.5) 1 (1.8) 
Individual patient medication related education  55 (85.9) 23 (41.8) 6 (10.9) 8 (14.5) 7 (12.7) 10 (18.2) 1 (1.8) 
Meetings with multidisciplinary team  52 (81.3) 11 (21.2) 4 (7.7) 13 (25) 12 (23.1) 10 (19.2) 2 (3.8) 
Medical ward round with multidisciplinary team 43 (67.2) 16 (37.2) 5 (11.6) 9 (20.9) 8 (18.6) 3 (7) 2 (4.7) 
Clinical pharmacy services for outpatients 
The provision of care in the outpatient setting was generally less frequent than 
the inpatient setting. The characteristics of services in the outpatient setting are 
provided in table 4. The most frequently performed activities included; providing 
general pharmaceutical care by 62.5% (n = 40) and meeting with the 
multidisciplinary team by 64.1% (n = 41). General pharmaceutical care for 
patients in an outpatient setting was performed by 40% (n = 16) of the 
respondents on a daily basis during weekdays, whereas, 32.5% (n = 13) were 
providing the care on an ‘ad hoc’ basis.  
 
Many of the respondents were providing pharmaceutical care for patients 
receiving dialysis (59.4%, n = 38) and transplantation (57.8%, n = 37). These 
activities were provided daily on weekdays by 34.2% (n = 13) and 35.2% (n = 
13) respectively.  Less frequently provided activities were; consulting for specific 
conditions including hemodialysis or peritoneal dialysis (34.4%, n = 22), other 
renal complications (31.3%, n = 20), acute kidney injury (14.1%, n = 9) and 
mineral bone disease (26.6%, n = 17) mostly on an ad hoc basis.  
 
Individual patient medication related education was performed by 59.4% (n = 
38) of the respondents, mostly either on an ‘ad hoc’ basis by 42.1% (n = 16), 
‘two to three times a week’ by 23.7% (n = 9) or ‘once a week’ by 21.1% (n = 8) 
of the respondents. Targeted disease specific medication reviews were again 
among the least frequently performed activities in the outpatient setting with 
only a quarter undertaking hypertension reviews (25%, n = 42), 34.4% doing 
vasculitis reviews (n = 22), and 32.8% doing anemia reviews (n = 21). 
  
Table 4: Characteristics of clinical pharmacy services you provide for OUTPATIENTS with CKD (N=64) 
Area of care 
Provision 





Daily Weekdays and 
Weekends 
2-3 
x/week Once/week Ad hoc  Missing 
n (%) n (%) n (%) n (%) n (%) n (%)  n (%) 
General pharmaceutical care  40 (62.5) 16 (40) 4 (10) 4 (10) 3 (7.5) 13 (32.5) 0 (0) 
Meetings with multidisciplinary team 41 (64.1) 3 (7.3) 2 (4.9) 10 (24.4) 13 (31.7) 9 (22) 1 (2.4) 
Individual patient medication related education  38 (59.4) 3 (7.9) 1 (2.6) 9 (23.7) 8 (21.1) 16 (42.1) 1 (2.6) 
Pharmaceutical care for patients receiving 
dialysis  38 (59.4) 13 (34.2) 3 (7.9) 5 (13.7) 3 (7.9) 13(34.2) 1(2.6) 
Pharmaceutical care for patients at 
transplantation /follow-up 37 (57.8) 13 (35.1) 2 (5.4) 7 (18.9) 5 (13.7) 9 (24.3) 1 (2.7) 
Medicines reconciliation  31 (48.4) 8 (25.8) 6 (19.4) 7 (22.6) 4 (12.9) 5 (16.1) 1 (3.2) 
Full medication regimen poly-pharmacy review 28 (43.8) 5 (17.9) 1 (3.6) 8 (28.6) 3 (10.7) 10(35.7) 1 (3.6) 
Targeted renal medication review: 
transplantation  29 (45.3) 7 (24.1) 1 (3.4) 6 (20.7) 5 (17.2) 10 (34.5) 0 (0) 
Targeted CKD renal medication review  27 (42.2) 1 (3.7) 1 (3.7) 5 (18.5) 4 (14.8) 14 (51.9) 1 (3.7) 
Targeted renal medication review: vasculitis  22 (34.4) 1 (4.5) 0 (0) 3 (13.6) 4 (18.2) 14 (63.6) 0 (0) 
Targeted renal medication review: anemia  21 (32.8) 1 (4.8) 2 (9.5) 2 (9.5) 7 (33.3) 9 (42.9) 0 (0) 
Targeted renal medication review: hypertension  16 (25) 1 (6.3) 1 (6.3) 2 (12.5) 2 (12.5) 9 (56.3) 1 (6.3) 
Consulting out-patients on hemodialysis or 
peritoneal dialysis  22 (34.4) 2 (9.1) 3 (13.6) 4 (18.2) 1 (4.5) 11 (50) 1 (4.5) 
Consulting outpatients with renal complication  20 (31.3) 1 (5) 1 (5) 7 (35) 2 (10) 9 (45) 0 (0) 
Consulting outpatients with mineral bone 
disease  17 (26.6) 1 (5.9) 1 (5.9) 2 (11.8) 5 (29.4) 8 (47.1) 0 (0) 
Consulting outpatients with acute kidney injury  9 (14.1) 1 (11.1) 0 (0) 1 (11.1) 1 (11.1) 6 (66.7) 0 (0) 
 
Additional roles of pharmacists to support delivery of services 
Additional roles undertaken by the pharmacist to support delivery of patient care 
are shown in table 5.  
 
The most frequently performed additional roles were delivering education and 
training for other pharmacy staff (90.6%, (n = 58), other healthcare 
professionals (84.4%, n = 54/64) and students (81.3%, n = 52). The least 
frequently performed activities were academic research (7.8%, n = 5) and care 
home support (9.4%, n = 6). A number of respondents were planning to 
perform these activities within the next 12 months, with a third (34.4%, n = 22) 
of respondents planning to undertake academic research. Few (3.1%, n = 2), 






















Table 5: Additional roles undertaken by the pharmacist to support delivery of 









No plans Missing 
n (%) n (%) n (%) n (%) 
Audits/service evaluations/quality improvements 46 (71.9) 15 (23.4) 1 (1.6) 2 (3.1) 
Care home support 6 (9.4) 2 (3.1) 52 (81.3) 4 (6.3) 
Academic research 5 (7.8) 22 (34.4) 33 (51.6) 4 (6.3) 
Providing education/training for other pharmacy staff 58 (90.6) 5 (7.8) 0 (0) 1 (1.6) 
Providing education/ training for other healthcare 
professionals 54 (84.4) 6 (9.4) 2 (3.1) 2 (3.1) 
Providing education/ training for students 52 (81.3) 6 (9.4) 5 (7.8) 1 (1.6) 
Providing education/ training for patient groups 31 (48.4) 9 (14.1) 21 (32.8) 3 (4.7) 
Providing education/ training for carers 29 (45.3) 6 (9.4) 25 (39.1) 4 (6.3) 
Providing mentoring for other pharmacy staff 56 (87.5) 5 (7.8) 2 (3.1) 1 (1.6) 
Providing mentoring for other healthcare professionals 32 (50) 7 (10.9) 21 (32.8) 4 (6.3) 
Involved in production of national level guidelines, 
strategy or policy 12 (18.7) 13 (20.3) 35 (54.7) 4 (6.3) 
Involved in production of in-house guidelines, strategy 
or policy 56 (87.5) 4 (6.3) 2 (3.1) 2 (3.1) 
Involved in drug and therapeutics committee 
submissions 48 (75) 7 (10.9) 7 (10.9) 2 (3.1) 
Participation in national working groups e.g. UKRPG 29 (45.3) 5 (7.8) 27 (42.2) 3 (4.7) 
High cost drugs- predict, plan and monitor new 
innovations in terms of business care, funding and 
reimbursement 










Development and implementation of clinical pharmacy practice  
Table 6 provides responses to the statements on the development and 
implementation of clinical pharmacy practice in relation to CFIR domains and 
constructs. 
 
Overall the respondents held positive views on the statements. However, of the 
64 respondents the majority (61%, n = 39) agreed or strongly agreed on the 
need for more evidence around the benefits of clinical pharmacy in CKD within 
the CFIR domain of ‘intervention characteristics: evidence strength’.  
 
The highest levels of agreement were received for the CFIR domain ‘process of 
implementation’ and specifically related to opinion leaders (social influences). 
Almost all agreed/strongly agreed with the statements, “the actions and views of 
renal specialists influence my practice” (95.3%, n = 61) and, “the actions and 
views of other members of my profession influence my practice” (89%, n = 57). 
 
Within the CFIR domain of ‘inner setting: learning climate and process’ there 
was clear disagreement with statements relating to having sufficient time to 
reflect on practice with more than half indicating they strongly disagree or 
disagree (56.2%, n = 36) and the ‘inner setting: available resources’ statement 
on having sufficient cover for continuation of the clinical services provided when 
not in the department with 68.8% indicating they strongly disagree or disagree 
(n = 44).  
 
The majority of respondents strongly agreed or agreed that they were burdened 
with having to provide other services taking them away from providing care 
(65.6%, n = 42). Almost two thirds of respondents strongly disagreed or 
disagreed that they had sufficient administrative support to facilitate their 
practice (65.6%, n = 42).  
 
The statement associated with the CFIR domain of ‘characteristics of individuals’ 
indicates that in relation to ‘self-efficacy’, a high proportion of respondents 
strongly agreed or agreed that they are confident in their abilities in general and 
in working as part of the multidisciplinary team (85.9%, n = 55).  
 
There was also strong agreement with statements relating to the ‘outer setting’ 
domain of the CFIR with nearly 60% of respondents strongly agreeing or 
agreeing to the ‘peer pressure’ statement “I feel that colleagues in other 
organizations are ahead in implementing the role” (59.4%, n = 38). 
Table 6: Development and implementation of clinical pharmacy practice. Responses to items within each of the CFIR domains 
(Median in bold) (N=64) 











    n (%) n (%) n (%) n (%) 
INTERVENTION 
CHARACTERISTICS: 
EVIDENCE STRENGTH  
I feel there is a need for more 
evidence for the benefits of my role  39 (61) 14(21.9) 9 (14.1) 2 (3.1) 
INTERVENTION 
CHARACTERISTICS: 
QUALITY / COST 
I feel that cost of service provision 
is a deterrent to the development 
of my role 
45 (70.3) 8 (12.5) 10 (15.6) 1 (1.6) 
CHARACTERISTICS OF 
INDIVIDUALS: SELF 
EFFICACY / PERSONAL 
ATTRIBUTES 
I am confident in my abilities 55 (85.9) 6 (9.3) 2 (3.2) 1 (1.6) 
I am confident in my ability as a 
member of the multidisciplinary 
team 
55 (85.9) 5 (7.8) 2 (3.2) 2 (3.2) 
OUTER SETTING: PEER 
PRESSURE 
I feel that colleagues in other 
organizations are ahead in 
implementing the role 
38 (59.4) 16 (25) 8 (12.5) 2 (3.2) 
Advice and guidance from 
professional organization such as 
UKRPG influence how I practise in 
my role 
50 (78.1) 9 (14.1) 4 (6.3) 1 (1.6)  
INNER SETTING: GOALS / 
FEEDBACK 
I have clear goals for what I want 
to achieve when I practise 49 (76.5) 12 (18.7) 2 (3.2) 1 (1.6) 
I have clear goals for developing 
clinical pharmacy services 41 (64.1) 13 (20.3) 8 (12.5) 2 (3.2) 
I have clear goals relating to my 
CPD needs 46 (71.9) 11 (17.2) 6 (9.3) 1 (1.6) 
INNER SETTING: 
AVAILABLE RESOURCES / 
ACCESS TO KNOWLEDGE & 
INFORMATION 
I feel I have sufficient time to 
practise in my role 11 (17.2) 5 (7.8) 47 (73.4) 1 (1.6) 
CFIR Domains and 
constructs Statement 
Strongly 








    n (%) n (%) n (%) n (%) 
INNER SETTING: 
AVAILABLE RESOURCES / 
ACCESS TO KNOWLEDGE & 
INFORMATION 
I feel that I have sufficient cover 
for continuation of the clinical 
services I provide when I am not in 
the department 
14 (21.9) 5 (7.8) 44 (68.8) 1 (1.6) 
I feel that I am burdened with 
having to provide other services 
that take me away from providing 
care for patient with CKD 
42 (65.6) 8 (12.5) 13 (20.4) 1 (1.6) 
I feel I have sufficient 
administrative support to facilitate 
my practice 
10 (15.7) 11 (17.2) 42 (65.6) 1 (1.6) 
I feel I have adequate access to 
patient information (case notes, lab 
data etc) to practise in my role 
59 (92.2) 2 (3.2) 2 (3.2) 1 (1.6) 
I have sufficient support from 
specialists to enable me to practise 
in my role 
53 (82.9) 8 (12.5) 2 (3.2) 1 (1.6) 
I feel I have adequate time to 
attend courses and conferences for 
my development 
17 (26.6) 11 (17.2) 33 (51.1) 1 (1.6) 
I feel I have adequate access to 
funds to allow me to attend courses 
and conferences to help 
development in my role 
13 (20.3) 11 (17.2) 39 (61) 1 (1.6) 
INNER SETTING: 
LEARNING CLIMATE AND 
PROCESS: REFLECTING & 
EVALUATING 
I feel that my clinical knowledge is 
valued and used by the 
multidisciplinary team 
57 (89) 5 (7.8) 1 (1.6) 1 (1.6) 
I am comfortable in my clinical 
pharmacy practice to try out new 
methods of service delivery 
42 (65.6) 11 (17.2) 10 (15.7) 1 (1.6) 
 












    n (%) n (%) n (%) n (%) 
 
INNER SETTING: LEARNING 
CLIMATE AND PROCESS: 
REFLECTING & EVALUATING 
 
I feel I have sufficient time to 
reflect and think about my 
clinical pharmacy practice 
13 (20.3) 14(21.9) 36 (56.2) 1 (1.6) 
I have ways of monitoring the 
quality of my clinical pharmacy 
practice caring for patients with 
CKD 
12 (18.7) 17 (26.6) 34 (53.1) 1 (1.6) 
PROCESS: OPINION LEADERS 
(SOCIAL INFLUENCES) 
The actions and views of other 
members of my profession 
influence my practice 
57 (89) 4 (6.3) 2 (3.2) 1 (1.6) 
The actions and views of renal 
specialists influence my practice 61 (95.3) 2 (3.2) 0 (0) 1 (1.6) 
I feel my role as a clinical 
pharmacist is not fully supported 
by my peers 
16 (25) 11 (17.2) 36 (56.3) 1 (1.6) 
I feel my role as clinical 
pharmacist for patients with CKD 
is not fully supported by my 
multidisciplinary team 
9 (14.1) 6 (9.3) 48 (75) 1 (1.6) 
I feel my role as a clinical 
pharmacist for patients with CKD 
is not fully supported by my 
organization 
17 (26.6) 13 (20.3) 33 (51.5) 1 (1.6) 
I feel my role as a clinical 
pharmacist for patients with CKD 
is not fully supported by 
specialists 
5 (7.8) 10 (15.6) 48 (75) 1 (1.6) 
PROCESS: OPINION LEADERS 
(SOCIAL INFLUENCES) 
The actions and views of other 
members of the multi-
disciplinary team influence my 
practice 
57 (89) 5 (7.8) 1 (1.6) 1 (1.6) 
 
Characteristics of prescribing practice 
Three quarters of the respondents (75%, n = 48) were qualified non-medical 
prescribers and were currently actively prescribing. Most of them were practicing 
independent prescribing (87.5 %, n= 42). More than half of the respondents had 
been registered with the United Kingdom General Pharmaceutical Council (GPhC) 
as prescribers for between one and five years (52.1%, n = 25). The respondents 
were prescribing in various areas related to CKD as shown in figure 1. 
 
 




























Development and implementation of prescribing practice  
Table 7 provides responses to statements derived from CFIR on the development 
and implementation of prescribing practice relating to CKD. The highest level of 
agreement was reported within the CFIR domain of ‘characteristics of individual: 
self-efficacy/personal attributes’. The majority of the participants (93.7%, n = 
45) indicated that they are competent to prescribe within the multidisciplinary 
team and 91.6% (n = 44) agreed that they are competent in continuing the 
prescribing of medicines initiated by others. In relation to the domain of 
‘characteristics of individuals: other personal attributes’ almost two thirds 
believed that patients would be treated more effectively if a pharmacist 
prescribes for them (66.7%, n = 32), while 73% (n = 35) believed prescribing is 
more cost-effective if done by the pharmacist. 
 
The highest levels of disagreement for statements related to the CFIR domain of 
‘process of implementation: construct of social influences’, (83.3%, n = 40) of 
the respondents disagreed about the fact that their prescribing is not fully 
supported by my multidisciplinary team and (79.1%, n = 38) disagreed that 
their prescribing was not fully supported by their organization. The lowest level 
of agreement was for, “My prescribing is not fully supported by specialists” 
(strongly agree/agree 4.2%, n = 2). 
 
Through responses to statements in the CFIR domain ‘intervention 
characteristics: evidence strength and quality’ more than half of respondents 
strongly agreed or agreed that felt there was a need for more evidence for the 
benefits of pharmacist prescribing for patients with CKD (56.2%, n = 27),  
 
There were mixed responses with statements relating to the ‘outer setting’ 
domain of the CFIR in relation to ‘peer pressure’. Responses to the statement “I 
feel that colleagues in other organizations are ahead in implementing pharmacist 
prescribing in their practice” indicated 52% (n = 25) agreed with the statement 
and 29.2% (n = 14) disagreeing. Almost two-third (64.6%, n = 31) of the 
respondents strongly agreed or agreed that ‘other professional organizations 
influence their prescribing practice’. 
Within the CFIR domain ‘inner setting: available resources’ for the statement on 
having ‘sufficient time to prescribe’ there was disparity in the responses among 
respondents. Around a third of the respondents (37.5%, n = 18) strongly agreed 
or agreed, while 39.6% (n = 19) strongly disagreed or disagreed and the 
remainder (18.7%, n = 9) neither agreed nor disagreed with the statement. 
 
There was a similar response to the statement related to the sufficiency of 
administrative support to facilitate their prescribing’ with (37.5%, n = 18) in 





Table 7: Development and implementation of prescribing practice. Responses to items within each of the CFIR domains 
(Median in bold) (N=48) 















& QUALITY / COST 
I feel there is a need for more 
evidence for the benefits of 
pharmacist prescribing for 
patients with CKD 
27(56.2) 12 (25) 7 (14.6) 2 (4.2) 
I feel that cost of service 
provision is a deterrent to the 
development of my prescribing 
practice 
25 (52.1) 9 (18.7) 12 (25) 2 (4.2) 
I feel that the cost of some drugs 
used in CKD are a deterrent to 
my prescribing 
6 (12.5) 10 (20.8) 30 (62.5) 2 (4.2) 
CHARACTERISTICS OF 
INDIVIDUALS: SELF 
EFFICACY / PERSONAL 
ATTRIBUTES 
I am confident in my ability to 
initiate prescribing of medicines 
for my patients 
38 (79.2) 5 (10.4) 3 (6.3) 2 (4.2) 
I lack confidence in switching 
patients from one drug to 
another when I prescribe 
5 (10.4) 12 (25) 29 (60.5) 2 (4.2) 
I am confident in my ability to 
prescribe for patients with CKD 
when they have been initiated on 
medicines by others 
41 (85.4) 3 (6.3) 2 (4.2) 2 (4.2) 
I am confident in my ability to 
prescribe within the 
multidisciplinary team 
43 (89.6) 3 (6.3) 0 (0) 2 (4.2) 
 
 











    n (%) n (%) n (%) n (%) 
CHARACTERISTICS OF 
INDIVIDUALS: SELF 
EFFICACY / PERSONAL 
ATTRIBUTES 
I lack competency to initiate 
prescribing of medicines for my 
patients 
6 (12.5) 6 (12.5) 34 (70.8) 2 (4.2) 
I am competent in continuing the 
prescribing of medicines initiated 
by others 
44 (91.6) 1 (2.1) 1 (2.1) 2 (4.2) 
I am competent to switch 
treatments (medicines) when I 
prescribe for my patients 
42 (87.5) 1 (2.1) 3 (6.3) 2 (4.2) 
I am competent to prescribe 












CFIR Domains and 
constructs Statement 
Strongly 











I feel anxious when initiating 
medicines for patients with CKD 12 (25) 12 (25) 22 (45.9) 2 (4.2) 
I feel anxious when prescribing 
medicines which have been 
initiated by others 
5 (10.4) 11 (22.9) 30 (62.5) 2 (4.2) 
I get professional satisfaction 
when initiating the prescribing 
for patients 
36 (75) 8 (16.7) 0 (0) 4 (8.3) 
I get professional satisfaction 
when prescribing medicines 
which have been initiated by 
others 
25 (52.1) 18 (37.5) 3 (6.3) 2 (4.2) 
If I prescribe for patients with 
CKD, I believe that patients will 
be treated more effectively 
32 (66.7) 11 (22.9) 3 (6.3) 2 (4.2) 
If I prescribe for patients with 
CKD, I believe that patients will 
have fewer adverse effects 
18 (37.5) 20 (41.6) 8 (16.7) 2 (4.2) 
If I prescribe for patients with 
CKD, I believe that patients will 
be treated more cost effectively 
35 (73) 9 (18.7) 1 (2.1) 3 (6.3) 
If I do not prescribe for patients 
with CKD, I believe that patients 
may come to harm 
14 (29.2) 11 (22.9) 21 (43.7) 2 (4.2) 
If I have to switch medications in 
stabilised patients, I believe that 
patient care may be 
compromised 

















    n (%) n (%) n (%) n (%) 
OUTER SETTING: PEER 
PRESSURE 
I feel that colleagues in other 
organizations are ahead in 
implementing pharmacist 
prescribing in their practice 
25 (52) 7 (14.6) 14 (29.2) 2 (4.2) 
Advice and guidance from 
professional organization such as 
UKRPG influence my prescribing 
activity 
31 (64.6) 12 (25) 2 (4.2) 3 (6.3) 
INNER SETTING: 
GOALS / FEEDBACK 
I have clear goals for what I 
want to achieve when I prescribe 
for patients with CKD 
40 (83.3) 3 (6.3) 3 (6.3) 2 (4.2) 
I have clear goals for developing 
services for patients with CKD 
using my prescribing skills 
25 (52) 11 (22.9) 9 (18.7) 3 (6.3) 
I have clear goals relating to my 
CPD around prescribing for 
patients with CKD 











CFIR Domains and 
constructs Statement 
Strongly 







    n (%) n (%) n (%) n (%) 
INNER SETTING: 
AVAILABLE 
RESOURCES / ACCESS 
TO KNOWLEDGE & 
INFORMATION 
I feel I have sufficient time to 
prescribe 18 (37.5) 9 (18.7) 19 (39.6) 2 (4.2) 
I feel that I have sufficient cover 
for continuation of the 
prescribing services I provide 
when I am not in the department 
12 (25) 1 (2.1) 33 (68.7) 2 (4.2) 
I feel that I am burdened with 
having to provide other services 
that take me away from 
prescribing 
31 (64.6) 2 (4.2) 13 (27.1) 2 (4.2) 
Prescribing systems in my 
organization facilitate me in 
prescribing 
24 (50) 12 (25) 10 (20.8) 2 (4.2) 
I feel I have sufficient 
administrative support to 
facilitate prescribing 
18 (37.5) 8 (16.7) 20 (41.7) 2 (4.2) 
I feel I have adequate access to 
patient information (case notes, 
lab data etc) to prescribe safely 
and effectively 





CFIR Domains and 
constructs Statement 
Strongly 








    n (%) n (%) n (%) n (%) 
INNER SETTING: 
AVAILABLE 
RESOURCES / ACCESS 
TO KNOWLEDGE & 
INFORMATION 
I have sufficient support from 
expert advice and specialists to 
enable me to prescribe safely 
and effectively 
41 (85.4) 4 (8.3) 0 (0) 3 (6.3) 
I feel I have adequate time to 
attend courses and conferences 
for my development as a 
prescriber 
16 (33.4) 7 (14.6) 23 (47.9) 2 (4.2) 
I feel I have adequate access to 
funds to allow me to attend 
courses and conferences for my 
development as a prescriber 






I feel able to express my own 
prescribing development needs 
and discuss these with 
colleagues 
33(68.7) 7 (14.6) 6 (12.5) 2 (4.2) 
I feel that my prescribing 
knowledge is valued and used by 
the multidisciplinary team 
40 (83.3) 3 (6.3) 3 (6.3) 2 (4.2) 
I am comfortable in my 
prescribing practice to try out 
new methods of service delivery 
34 (70.8) 8 (16.7) 4 (8.3) 2 (4.2) 
I feel I have sufficient time to 
reflect and think about my 
prescribing practice 
16 (33.4) 10 (20.8) 19 (39.6) 2 (4.2) 
I have ways of monitoring the 
quality of my prescribing 21 (43.8) 10 (20.8) 15 (31.3) 2 (4.2) 
 
CFIR Domains and 




Disagree  Missing 




The actions and views of other 
members of the multi-
disciplinary team influence my 
prescribing activity 
40 (83.3) 5 (10.4) 1 (2.1) 2 (4.2) 
The actions and views of other 
members of my profession 
influence my prescribing activity 
36 (75) 8 (16.7) 2 (4.2) 2 (4.2) 
The actions and views of renal 
specialists influence my 
prescribing activity 
43 (89.6) 3 (6.3) 0 (0) 2 (4.2) 
My prescribing is not fully 
supported by my peers 6 (12.5) 7 (14.6) 33 (68.8) 2 (4.2) 
My prescribing is not fully 
supported by my 
multidisciplinary team 
2 (4.2) 4 (8.3) 40 (83.3) 2 (4.2) 
My prescribing is not fully 
supported by my organization 3 (6.3) 4 (8.3) 38 (79.1) 3 (6.3) 
My prescribing is not fully 
supported by specialists 2 (4.2) 5 (10.4) 37 (77.1) 4 (8.3) 
The structures and processes 
within my organization influence 
my prescribing activity 
31 (64.6) 8 (16.7) 7 (14.6) 2 (4.2) 
Increased scrutiny of my 
prescribing by my organization is 
an influence on my prescribing 






This study has provided evidence that the vast majority of UKRPG pharmacists 
practicing in CKD are independent prescribers, providing general pharmaceutical 
care to CKD patients in general and specifically to dialysis and kidney transplant 
patients. Respondents reported being confident in their own abilities and feeling 
comfortable in trying new ways of working. In relation to prescribing, most were 
confident in their abilities to initiate prescribing for individual patients within 
their areas of competence.  
This work has been underpinned with theoretical approaches throughout its 
planning and execution. The use of CFIR has provided a framework that has 
enabled the research team to develop a comprehensive understanding of the 
facilitators and barriers to the implementation of clinical services in general and, 
in particular, new models of prescribing practice in CKD. Facilitators for the 
implementation of new services such as prescribing practice included; 
experience of service provision and confidence in their abilities (characteristics of 
individuals); having support from multidisciplinary team members (process); 
having clear goals for further development (inner setting) and support from 
professional organizations (outer setting). Barriers to implementing new models 
of practice included a lack of evidence for the benefit of new clinical pharmacy 
services in CKD. This was particularly true for the development of prescribing 
practice (intervention characteristics/evidence and quality). The lack of funding 
to support clinical pharmacy services was also considered a barrier to service 
development (inner setting/available resources). Many respondents felt 
burdened by having to provide ‘core’ clinical and other non-clinical services 
(inner setting/available resources).  
Graham-Clarke et al describe the facilitators and barriers to implementation of 
non-medical prescribing in a systematic review. It included 42 papers and 
reported on the complex interdependent interplay of themes that could act as 
facilitators or barriers depending on particular circumstances.23 Facilitators 
identified included trust, understanding and confidence of the multidisciplinary 
team in the non-medical prescribing role. These social influences are also 
reflected in the results of this present study where pharmacist respondents felt 
that they have the support of the multi-disciplinary team, their organization and 
specialists to prescribe. They also expressed high level of self-efficacy with many 
indicating that they felt confident and competent particularly in their prescribing 
practice. Graham-Clarke et al also reported that cost and budget limitations were 
among the main barriers to nonmedical prescribing.23 In this present study 
respondents expressed a broad range of responses in relation to resource 
availability for aspects of prescribing practice such as having sufficient time to 
prescribe and having sufficient administrative support. There was, however, a 
clear desire to have more resources to ensure continuity of prescribing services 
during periods of staff absence. A majority of respondents also indicated a lack 
of resource to cover other services that take them away from the prescribing 
role. Given this, it is likely that structures and processes of care provision vary 
across different organizations resulting in operational differences and a 
differential impact of these factors on patient care.   
While respondents, in this study, were practicing almost exclusively in secondary 
care, it should be noted that, there is potential for community pharmacists to 
contribute to CKD management. A study, published in 2014, reported that 
community pharmacists are willing to have more input to the care of patients 
with CKD. It noted that there is a need to increase awareness among patients to 
the availability of resources and services in the community.24 A recent study, in 
Scotland, reported that there is a growing pharmacy workforce in general 
medical practices for the delivery of clinical and prescribing services.25 There 
may be potential for involvement of this workforce in the shared care of patients 
with CKD. Al Hamarneh et al. reported that pharmacists in the community 
setting can contribute to improvements in the care of patient with CKD by 
providing clinical services such as; medication management, patient education, 
and prescribing.14  
Some time ago the visionary UK National Renal Workforce Planning Group 
highlighted that pharmacist prescribing will impact on the level and type of 
services provided by pharmacists and that variations in levels of renal pharmacy 
service provision would be narrowed.26 It is therefore heartening that this survey 
shows that many respondents were active prescribers in CKD and providing a 
range of clinical services in a variety of settings. However, there is a need for 
further robust research in the area of nonmedical prescribing to add to the 
limited evidence base that shows it provides safe, effective and cost-effective 
care.10,15  
 
In view of this, it is of some concern that few of the specialised renal 
pharmacists in this study were involved in any research. Previous studies have 
reported a variety of barriers to pharmacists engaging in research activities 
including; lack of time, availability of funding, lack of research knowledge and 
logistic issues.27 To enhance this strategies have been proposed.28,29,30  
Collaboration of academics with professional organizations can be an attractive 
tool to enhance the development of a research culture, ethos and skill base in 
pharmacists.28,30 A UK survey of community pharmacies in London and Essex 
reported that 43% of respondents had participated in some form of pharmacy 
practice research, which indicates a willingness to engage.31 A recently published 
study on the views and experiences of practicing pharmacists to research 
reported that a minority of experienced secondary care pharmacists are involved 
in performing research based activities. However, again participants showed an 
interest in being involved in research.32 
 
Specific barriers to the development of clinical and prescribing services reported 
in this study were time, resources, training and administrative support. These 
challenges are not unique to this study and have been reported repeatedly in the 
literature.9,10 A key facilitator to service development is provision of support 
through education and training. Studies suggest that clinical pharmacy education 
sessions had positive impacts on the management of CKD and that the cost 
expended on educational sessions are warranted to improve patient outcomes.33  
 
One of the strengths to this study is that it is based on the use of a theoretical 
framework. Using theory within healthcare research is developing at pace and is 
leading to enhanced robustness and rigour.34 The UK Medical Research Council 
Framework for Developing and Evaluating Complex Interventions advocates the 
systematic use of appropriate theory to develop or evaluate an intervention or 
new services.35 Using the CFIR has resulted in findings that offer an original 
contribution to the evidence base around structures, processes, barriers and 
facilitators related to UK pharmacy service provision in CKD. Respondents were 
from all geographical areas of the UK and so, in this respect, the results are 
likely to reflect the breadth of UK practice and any difference in healthcare 
delivery in the devolved nations in the UK. Limitations include the fact that the 
response rate was around 50% and it could be considered that this may 
compromise the integrity of the findings. It should be noted, however, that such 
a response rate for a national online survey is commendable given the generally 
poor responses rate for such methods when applied to busy healthcare 
professionals.36 Part of the reason for a reduced number of responses may relate 
to the desire to carry out a theoretically based, robust and comprehensive study. 
As a result, the questionnaire may have been considered overly long and 
involved for some potential respondents. In addition, the research team aspired 
to be as economically and environmentally efficient through online dissemination 
of the questionnaire. Questionnaire design and survey method have been shown 
to have an impact on response rates and this may have been the case in this 
survey.37 This was a self-completion questionnaire and as such it was not 
possible to confirm or triangulate the validity of the responses. These could have 
been influenced by a number of biases including; non-response, social 
desirability and conformity, acquiescence and prestige bias.38 Furthermore, 
members of a professional network, like the UKRPG, may not be truly 
representative of a wider population of clinical pharmacists. Patients with CKD 
may also be managed by non-renal specialist pharmacists and their views on 
services to these patients may have added another dimension to the results. In 
addition, all participants were practicing in secondary care and so the results 
should obviously be viewed in this context. As noted above, clinical pharmacy 
services are developing rapidly in other sectors such as primary care in the UK 
and as such it would be appropriate to consider this in future studies.  
 
Despite these limitations, it is evident that UK renal specialist pharmacists are 
highly involved in aspects of care of those with CKD, both in outpatient and 
inpatient settings.  This includes general pharmaceutical care and more 
specialised care in dialysis and transplantation. A higher proportion of 
respondents provided inpatient services which is perhaps to be expected, given 
that the role of the specialist clinical pharmacist is more established in the 
hospital sector in the UK at present. However, there may be scope to extend this 
to outpatient settings and primary care. This may be achieved through further 
development of pharmacist prescribing practice arising from a policy related 
aspiration for all clinical pharmacists to be independent prescribers and have 
responsibility for their own case load of patients.39  
The Royal Pharmaceutical Society and UKRPG have produced a professional 
curriculum for renal expert professional practice.15 The statements within the 
curriculum provide descriptions of the domains and levels of competency for 
renal specialists to benchmark their practice.15 This may have facilitated the 
development of practice and have helped contribute to the high self-reported 
levels of confidence and competence. Such expert professional curricula could 
also be used to help describe and benchmark the requirements for structures, 
processes and outcomes of care in renal practice. Al Raiisi et al have highlighted 
the lack of published detail relating to the structures and processes of practice in 
CKD.10 There is also a lack of agreement on what constitute appropriate outcome 
measures for studies exploring clinical pharmacy services in patients with CKD 
and therefore a lack of consistency of choice and use of outcomes in studies. 
This lack of detail greatly reduces the usefulness of the evidence generated 
about the nature and extent of the care. The consequence of this is that it 
cannot be easily replicated or the results pooled in synthesis and meta-analysis 
type analysis.  
 
This is highly relevant since in this study respondents expressed a desire to 
develop and implement innovative services to improve patient outcomes. An 
example of such innovation includes the RCT by Ishani et al’s 41 on assessing the 
role of interprofessional team in CKD management using telehealth. This study 
showed that telehealth is a feasible care delivery strategy but more detailed 
information on the structures and processes of this model of care and clarity on 
the theoretical basis for the intervention still need to be provided.41 A more 
detailed evidence base for such services that is well founded in a theoretical 
basis and robustly researched and reported will enable the connection of 
evidence to the development of care provision.42,43  
There are several potential avenues for further research. It is evident that there 
is a high proportion of pharmacist prescribers working CKD and healthcare policy 
is stimulating the development of nonmedical prescribing practice. In addition to 
the need for further high-quality outcomes-based research there is a need for 
qualitative research to allow a more in-depth exploration into the role of the 
pharmacist in prescribing for patients with CKD.  
 
Conclusion 
Results of this survey indicate high levels of clinical practice including wide-
spread non-medical prescribing activity. This survey has captured detailed 
information on pharmacists’ behavior and experiences in the care of patients 
with CKD. Through robust application of theoretical approaches using the CFIR it 
has also enabled the identification of barriers and facilitators for the 
development of clinical pharmacy and pharmacist prescribing practice. Lack of 
availability of resource to allow pharmacists to undertake additional non-core 
clinical roles could be considered a significant barrier to further development of 
clinical pharmacy practices including prescribing. There is also a lack of 
involvement in and skills base for research among respondents. Further work is 
planned using qualitative methods to explore these matters in more depth. 
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